The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Open accessAbstract
Redox homeostasis is essential for the maintenance of diverse cellular processes. Cancer cells have higher levels of reactive oxygen species (ROS) than normal cells as a result of hypermetabolism, but the redox balance is maintained in cancer cells due to their marked antioxidant capacity. Recently, anticancer therapies that induce oxidative stress by increasing ROS and/or inhibiting antioxidant processes have received significant attention. The acceleration of accumulative ROS disrupts redox homeostasis and causes severe damage in cancer cells. In this review, we describe ROS-inducing cancer therapy and the anticancer mechanism employed by prooxidative agents. To understand the comprehensive biological response to certain prooxidative anticancer drugs such as 2-methoxyestradiol, buthionine sulfoximine, cisplatin, doxorubicin, imexon, and motexafin gadolinium, we propose and visualize the drug-gene, drug-cell process, and drug-disease interactions involved in oxidative stress induction and antioxidant process inhibition as well as specific side effects of these drugs using pathway analysis with a big data-based text-mining approach. Our review will be helpful to improve the therapeutic effects of anticancer drugs by providing information about biological changes that occur in response to prooxidants. For future directions, there is still a need for pharmacogenomic studies on prooxidative agents as well as the molecular mechanisms underlying the effects of the prooxidants and/or antioxidant-inhibitor agents for effective anticancer therapy through selective killing of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931 · cited 1×
“A mild level of ROS regulates cell development and homeostasis, whereas a high level inflicts severe cellular damage [50, 51].”
BackgroundCisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Metals, Toxicity and Oxidative Stress
Valko, M., Morris, H., & Cronin, M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053764635 · Cited by 5,018 · cited 1×
“As previously demonstrated, the impairment of redox homeostasis mediated by an excess of oxidized biological molecules is associated with cellular toxic effects [12].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“Accordingly, increased drug efflux through the transporter leads to drug resistance [119].”
BackgroundOxidative stress: oxidants and antioxidants
Sies, H. (1997) · Experimental Physiology · doi:10.1113/expphysiol.1997.sp004024 · Cited by 4,566
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Oxidative stress: a concept in redox biology and medicine
Sies, H. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.002 · Cited by 2,991
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
Zelko, I. N., Mariani, T. J., & Folz, R. J. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00905-x · Cited by 2,212
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Diversity of structures and properties among catalases
Chelikani, P., Fita, I., & Loewen, P. C. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3206-5 · Cited by 1,700
Griffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683 · cited 2×
“Buthionine sulfoximine Binds to enzyme related to GSH synthesis [101]”
BackgroundBeyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Potential Role of Carotenoids as Antioxidants in Human Health and Disease
Fiedor, J., & Burda, K. (2014) · Nutrients · doi:10.3390/nu6020466 · Cited by 1,420
The changing faces of glutathione, a cellular protagonist
Pompella, A., Visvikis, A., Paolicchi, A., Tata, V. D., & Casini, A. F. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00504-5 · Cited by 1,359
Oxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Generation of reactive oxygen species by the mitochondrial electron transport chain
Liu, Y., Fiskum, G., & Schubert, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00744.x · Cited by 1,260 · cited 2×
“Most endogenous ROS are mainly generated in the mitochondrial electron transport chain (ETC) and NADPH oxidase complex (NOX) [13, 14].”
BackgroundOxidative stress: the paradox of aerobic life
Davies, K. J. A. (1995) · Biochemical Society Symposia · doi:10.1042/bss0610001 · Cited by 1,146
Reactive oxygen species: from health to disease
Brieger, K., Schiavone, S., Miller Jr., F. J., & Krause, K.-H. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13659 · Cited by 1,133
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Aspects of the Structure, Function, and Applications of Superoxide Dismutas
Bannister, J. V., Bannister, W. H., & Rotilio, G. (1987) · Critical Reviews in Biochemistry · doi:10.3109/10409238709083738 · Cited by 856
Superoxide dismutase as a target for the selective killing of cancer cells
Huang, P., Feng, L., Oldham, E. A., Keating, M. J., & Plunkett, W. (2000) · Nature · doi:10.1038/35030140 · Cited by 842
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
[11] Redox potential of GSH/GSSG couple: Assay and biological significance
Jones, D. P. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)48630-2 · Cited by 812
Gupta, S. C., Kim, J. H., Prasad, S., & Aggarwal, B. B. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9235-2 · Cited by 806
Cancer cell killing via ROS: To increase or decrease, that is the question
Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7067 · Cited by 790
Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777 · cited 1×
“Cisplatin, a well-known anticancer agent with cross-linking activity, directly damages mitochondrial DNA (mtDNA), which leads to ETC impairment [76].”
BackgroundReactive Oxygen Species: A Key Constituent in Cancer Survival
Kumari, S., Badana, A. K., G, M. M., G, S., & Malla, R. (2018) · Biomarker Insights · doi:10.1177/1177271918755391 · Cited by 777
Oxidative stress and apoptosis: Impact on cancer therapy
Ozben, T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20874 · Cited by 751
Protein kinase C signaling and oxidative stress
Gopalakrishna, R., & Jaken, S. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00221-5 · Cited by 701 · cited 1×
“Selenocompounds exhibit anticancer effects through potentiating the antioxidative defense system from ROS-induced cellular damage [37, 38] and through redox modification of redox-active, cysteine-rich regions of protein kinase C (PKC), a receptor for tumor promoters [39, 40].”
BackgroundAutophagy and multidrug resistance in cancer
Li, Y.-J., Lei, Y.-H., Yao, N., Wang, C.-R., Hu, N., Ye, W.-C., Zhang, D.-M., & Chen, Z.-S. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0219-2 · Cited by 665
Antioxidants can increase melanoma metastasis in mice
Le Gal, K., Ibrahim, M. X., Wiel, C., Sayin, V. I., Akula, M. K., Karlsson, C., Dalin, M. G., Akyürek, L. M., Lindahl, P., Nilsson, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3740 · Cited by 632 · cited 1×
“Indeed, the GSH/GSSG ratio tends to be lower in circulating melanoma or metastatic cancers, suggesting that late-stage cancers have better antioxidant processes than early-stage cancers [62, 63].”
Background(2000) · PubMed · Cited by 614
Induction of reactive oxygen species: an emerging approach for cancer therapy
Zou, Z., Chang, H., Li, H., & Wang, S. (2017) · Apoptosis · doi:10.1007/s10495-017-1424-9 · Cited by 582
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Minotti, G., & Aust, S. D. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75755-x · Cited by 544
Targeting antioxidants for cancer therapy
Glasauer, A., & Chandel, N. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.017 · Cited by 499
Mehta, M. P., Rodrigus, P., Terhaard, C. H. J., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 463
Cytotoxicity of dietary flavonoids on different human cancer types
Sak, K. (2014) · Pharmacognosy Reviews · doi:10.4103/0973-7847.134247 · Cited by 461
Davies, K. J. A. (1999) · International Union of Biochemistry and Molecular Biology: Life · doi:10.1080/152165499307404 · Cited by 453
Current Knowledge on the Importance of Selenium in Food for Living Organisms: A Review
Kieliszek, M., & Błażejak, S. (2016) · Molecules · doi:10.3390/molecules21050609 · Cited by 448
Reactive oxygen species and the bacterial response to lethal stress
Zhao, X., & Drlica, K. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2014.06.008 · Cited by 446
Aykin-Burns, N., Ahmad, I. M., Zhu, Y., Oberley, L. W., & Spitz, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20081258 · Cited by 433
Glutathione: A Vital Lens Antioxidant
GIBLIN, F. J. (2000) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2000.16.121 · Cited by 412
Blanco, J. G., Sun, C.-L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8987 · Cited by 372
Martin, K. R., & Barrett, J. C. (2002) · Human & Experimental Toxicology · doi:10.1191/0960327102ht213oa · Cited by 363
Selenium: a double-edged sword for defense and offence in cancer
Brozmanová, J., Mániková, D., Vlčková, V., & Chovanec, M. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0595-8 · Cited by 333
Kang, Y. J., Chen, Y., & Epstein, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12610 · Cited by 303
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.
Soria, J., Jang, S. J., Khuri, F. R., Hassan, K. A., Liu, D., Hong, W. K., & Mao, L. (2000) · PubMed · Cited by 299
ROS-modulated therapeutic approaches in cancer treatment
Raza, M. H., Siraj, S., Arshad, A., Waheed, U., Aldakheel, F., Alduraywish, S., & Arshad, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2464-9 · Cited by 297
Fluorescence-based microtiter plate assay for glutamate–cysteine ligase activity
White, C. C., Viernes, H., Krejsa, C. M., Botta, D., & Kavanagh, T. J. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00143-x · Cited by 293
Mãrtensson, J., Meister, A., & Mrtensson, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4656 · Cited by 286
2‐Methoxyestradiol, a Promising Anticancer Agent
Lakhani, N. J., Sarkar, M. A., Venitz, J., & Figg, W. D. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.2.165.32088 · Cited by 274
Glutathione defense mechanism in liver injury: Insights from animal models
Chen, Y., Dong, H., Thompson, D. C., Shertzer, H. G., Nebert, D. W., & Vasiliou, V. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.008 · Cited by 251
Activation of the Nrf2–ARE signaling pathway: a promising strategy in cancer prevention
Giudice, A., & Montella, M. (2006) · BioEssays · doi:10.1002/bies.20359 · Cited by 234
Kotamraju, S., Chitambar, C. R., Kalivendi, S. V., Joseph, J., & Kalyanaraman, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111604200 · Cited by 233
Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species
Miki, H., & Funato, Y. (2012) · Journal of Biochemistry · doi:10.1093/jb/mvs006 · Cited by 225
The Role of Reactive Oxygen Species in Regulating T Cell-mediated Immunity and Disease
Yarosz, E. L., & Chang, C.-H. (2018) · Immune Network · doi:10.4110/in.2018.18.e14 · Cited by 214 · cited 1×
“A mild level of ROS regulates cell development and homeostasis, whereas a high level inflicts severe cellular damage [50, 51].”
BackgroundNADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology
Meitzler, J. L., Antony, S., Wu, Y., Juhasz, A., Liu, H., Jiang, G., Lu, J., Roy, K., & Doroshow, J. H. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5603 · Cited by 201
Tavsan, Z., & Kayali, H. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109004 · Cited by 190
Yue, T.-L., Wang, X., Louden, C. S., Gupta, S., Pillarisetti, K., Gu, J.-L., Hart, T. K., Lysko, P. G., & Feuerstein, G. Z. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.951 · Cited by 187
Aoyama, K., & Nakaki, T. (2015) · Molecules · doi:10.3390/molecules20058742 · Cited by 183
Cushman, M., He, H.-M., Katzenellenbogen, J. A., Lin, C. M., & Hamel, E. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00012a003 · Cited by 183
Glutathione Depletion Induces Heme Oxygenase‐1 (HSP32) mRNA and Protein in Rat Brain
Ewing, J. F., & Maines, M. D. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03315.x · Cited by 178
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Gharavi, N., Haggarty, S., & S. El-Kadi, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315035 · Cited by 174
Mechanism of action of 2-methoxyestradiol: new developments
Mooberry, S. L. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.001 · Cited by 173
Bai, X., Chen, Y., Hou, X., Huang, M., & Jin, J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1197239 · Cited by 172
2-Methoxyestradiol—Biology and mechanism of action
Mueck, A. O., & Seeger, H. (2010) · Steroids · doi:10.1016/j.steroids.2010.02.016 · Cited by 171
Pro-Oxidant Natural Products as Anticancer Agents
Martin-Cordero, C., Jose Leon-Gonzalez, A., Manuel Calderon-Montano, J., Burgos-Moron, E., & Lopez-Lazaro, M. (2012) · Current Drug Targets · doi:10.2174/138945012802009044 · Cited by 171
Motexafin gadolinium: A novel redox active drug for cancer therapy
Magda, D., & Miller, R. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.002 · Cited by 162
Chen, Y., Yang, Y., Miller, M. L., Shen, D., Shertzer, H. G., Stringer, K. F., Wang, B., Schneider, S. N., Nebert, D. W., & Dalton, T. P. (2007) · Hepatology · doi:10.1002/hep.21635 · Cited by 161
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
Kilic, U., Kilic, E., Tuzcu, Z., Tuzcu, M., Ozercan, I. H., Yilmaz, O., Sahin, F., & Sahin, K. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-7 · Cited by 160
Targeting Nrf2 Signaling to Combat Chemoresistance
No, J. H., Kim, Y.-B., & Song, Y. S. (2014) · Journal of Cancer Prevention · doi:10.15430/jcp.2014.19.2.111 · Cited by 146
Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., & Waes, C. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1393 · Cited by 146
Are peroxiredoxins tumor suppressors?
Neumann, C. A., & Fang, Q. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.007 · Cited by 133
Wang, J., Luo, B., Li, X., Lu, W., Yang, J., Hu, Y., Huang, P., & Wen, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.272 · Cited by 133
Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity
Sofia Waissbluth, A., & Daniel, S. J. (2013) · Hearing Research · doi:10.1016/j.heares.2013.02.002 · Cited by 128
Ayer, A., Gourlay, C. W., & Dawes, I. W. (2014) · FEMS Yeast Research · doi:10.1111/1567-1364.12114 · Cited by 125
Antioxidant inhibitors for cancer therapy
Kong, Q., & Lillehei, K. O. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90036-6 · Cited by 124
Role of NADPH Oxidase-Mediated Reactive Oxygen Species in Podocyte Injury
Chen, S., Meng, X., & Zhang, C. (2013) · BioMed Research International · doi:10.1155/2013/839761 · Cited by 119
Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role
Helm, C. W., & States, J. C. (2009) · Journal of Ovarian Research · doi:10.1186/1757-2215-2-2 · Cited by 110
Abiko, Y., Miura, T., Phuc, B. H., Shinkai, Y., & Kumagai, Y. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.05.013 · Cited by 107
Metastasis and Oxidative Stress: Are Antioxidants a Metabolic Driver of Progression?
Peiris‐Pagès, M., Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. P. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.008 · Cited by 104
Induction of mitochondrial changes in myeloma cells by imexon
Dvořáková, K., Waltmire, C. N., Payne, C. M., Tome, M. E., Briehl, M. M., & Dorr, R. T. (2001) · Blood · doi:10.1182/blood.v97.11.3544 · Cited by 91
Dvořáková, K., Payne, C. M., Tome, M. E., Briehl, M. M., McClure, T. D., & Dorr, R. T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00380-4 · Cited by 89
Gopalakrishna, R., Chen, Z.-H., & Gundimeda, U. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0335 · Cited by 87
KRas, ROS and the initiation of pancreatic cancer
Storz, P. (2017) · Small GTPases · doi:10.1080/21541248.2016.1192714 · Cited by 82 · cited 1×
“Due to uncontrolled metabolic processes during hyperproliferation, cancer cells have a higher basal ROS level than normal cells [7].”
BackgroundDjavaheri‐Mergny, M., Wietzerbin, J., & Besançon, F. (2003) · Oncogene · doi:10.1038/sj.onc.1206356 · Cited by 79
Wondrak, G. T. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.035 · Cited by 73
2-Methoxyestradiol Does Not Inhibit Superoxide Dismutase
Kachadourian, R., Liochev, S. I., Cabelli, D. E., Patel, M. N., Fridovich, I., & Day, B. J. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2455 · Cited by 73
Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol
Hagen, T., D’Amico, G., Quintero, M., Palacios‐Callender, M., Hollis, V., Lam, F., & Moncada, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.204 · Cited by 71
New Challenges to Study Heterogeneity in Cancer Redox Metabolism
Benfeitas, R., Uhlén, M., Nielsen, J., & Mardinoğlu, A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00065 · Cited by 70
Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
Telkoparan‐Akillilar, P., Süzen, S., & Saso, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082025 · Cited by 69
Selenium or No Selenium- That Is the Question in Tumor Patients: A New Controversy
Mücke, R., Schomburg, L., Büntzel, J., Kisters, K., Micke, O., & German Working Group Trace Elements and Electrolytes in Oncology-AKTE (2010) · Integrative Cancer Therapies · doi:10.1177/1534735410367648 · Cited by 65
Catalysis of Thiol/Disulfide Exchange
Xiao, R., Lundström-Ljung, J., Holmgren, A., & Gilbert, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411476200 · Cited by 65
ROS Modulator Molecules with Therapeutic Potential in Cancers Treatments
Nicco, C., & Batteux, F. (2017) · Molecules · doi:10.3390/molecules23010084 · Cited by 61
Li, Y., Seacat, A. M., Kuppusamy, P., Zweier, J. L., Yager, J. D., & Trush, M. A. (2002) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(02)00073-6 · Cited by 58
Enns, G. M., Moore, T., Le, A. T., Atkuri, K. R., Shah, M. K., Cusmano‐Ozog, K. P., Niemi, A., & Cowan, T. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100001 · Cited by 54
Kataoka, M., Schumacher, G., Cristiano, R. J., Atkinson, E. N., Roth, J. A., & Mukhopadhyay, T. (1998) · PubMed · Cited by 51
Benfeitas, R., Bidkhori, G., Mukhopadhyay, B., Klevstig, M., Arif, M., Zhang, C., Lee, S., Çınar, R., Nielsen, J., Uhlén, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.057 · Cited by 47
Radioimmunoassay and Metabolism of the Catechol Estrogen 2-Hydroxyestradiol
河野, 伸., Merriam, G. R., Brandon, D. D., Loriaux, D. L., & Lipsett, M. B. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-150 · Cited by 40
Abdelhamid, G., & El‐Kadi, A. O. S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.01.005 · Cited by 36
Moulder, S. L., Dhillon, N., Ng, C. S., Hong, D. S., Wheler, J. J., Naing, A., Tse, S., LaPaglia, A., Dorr, R. T., Hersh, E. M., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9273-1 · Cited by 35
Pretreatment with Mangafodipir Improves Liver Graft Tolerance to Ischemia/Reperfusion Injury in Rat
Mosbah, I. B., Mouchel, Y., Pajaud, J., Ribault, C., Lucas, C., Laurent, A., Boudjéma, K., Morel, F., Corlu, A., & Compagnon, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050235 · Cited by 35
Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells
Dvorakova, K., Payne, C. M., Landowski, T. H., Tome, M. E., Halperin, D. S., & Dorr, R. T. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200211000-00007 · Cited by 24
Motexafin gadolinium: a novel radiosensitizer for brain tumors
Francis, D., Richards, G. M., Forouzannia, A., Mehta, M. P., & Khuntia, D. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903179325 · Cited by 17
Cited by
Reactive Oxygen Species Signaling and Oxidative Stress: Transcriptional Regulation and Evolution
Hong, Y., Boiti, A., Vallone, D., & Foulkes, N. S. (2024) · Antioxidants · doi:10.3390/antiox13030312 · Cited by 696
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Sadiq, I. Z. (2023) · Current Molecular Medicine · doi:10.2174/1566524022666211222161637 · Cited by 263
Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting
Parma, B., Ramesh, V., Gollavilli, P. N., Siddiqui, A., Pinna, L., Schwab, A., Marschall, S., Zhang, S., Pilarsky, C., Napoli, F., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02049-8 · Cited by 46
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
Liu, Z., Wang, H., Hu, C., Wu, C., Wang, J., Hu, F., Fu, Y., Wen, J., & Zhang, W. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03449-6 · Cited by 45
Metadata
- Authors
- Kim, S. J., Kim, H. S., & Seo, Y. R.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2019-12-20
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2995708286
- Cited by
- 406
- References
- 112
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.